February 23, 2018 / 12:09 PM / 6 months ago

BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies

Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc:

* BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES

* BELLICUM - RECEIVED NOTIFICATION FROM FDA OUTLINING CRITERIA REQUIRED FOR LIFTING CLINICAL HOLD ON U.S. STUDIES OF BPX-501

* BELLICUM PHARMACEUTICALS INC - CLINICAL HOLD DOES NOT AFFECT COMPANY'S BP-004 REGISTRATION TRIAL IN EUROPE

* BELLICUM - PLANS TO IMPLEMENT REVISIONS TO U.S. STUDY PROTOCOLS, ADDITION OF MORE COMPREHENSIVE MONITORING, MANAGEMENT OF NEUROTOXICITY FOR BPX-501 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below